Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics Inc
(NQ:
ALLO
)
2.890
+0.030 (+1.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
November 09, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
November 03, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for Allogene Therapeutics
September 22, 2022
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings:
Via
Benzinga
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
November 02, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
October 31, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
October 26, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
October 11, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
October 06, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Apple, Amazon, HP And Other Big Losers From Friday
August 29, 2022
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
September 22, 2022
Gainers
Via
Benzinga
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
August 10, 2022
Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
August 29, 2022
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
August 10, 2022
Via
Benzinga
Allogene Therapeutics: Q2 Earnings Insights
August 09, 2022
Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
July 20, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
July 15, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 15, 2022
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
June 03, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Allogene Therapeutics
June 03, 2022
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 17, 2022
Via
Benzinga
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
May 10, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
U.S. FDA Grants Orphan-Drug Designation for Allogene's ALLO-605 for multiple myeloma
April 27, 2022
Allogene Therapeutics, Inc. (Nasdaq: ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with...
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030
April 21, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from...
Via
FinancialNewsMedia
Allogene's Preclinical Data Show Healthy Donor-Derived Allogeneic CAR T Cells Have Better Immune Fitness, Killing Activity
March 23, 2022
Allogene Therapeutics Inc (NASDAQ: ALLO) announced the
Via
Benzinga
Recap: Allogene Therapeutics Q4 Earnings
February 23, 2022
Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.